Skip to content
10-Q

Quarterly Report

Royalty Pharma plc RPRX

0001802768-25-000027

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt Q1 2025 · Mar 31, 2025 $6.62B
Long Term Debt Q1 2025 · Dec 31, 2024 $6.61B
Short Term Debt Q1 2025 · Mar 31, 2025 $998.61M
Short Term Debt Q1 2025 · Dec 31, 2024 $997.77M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.09B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $929.03M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.18B
Current Liabilities Q1 2025 · Dec 31, 2024 $1.25B
Total Liabilities Q1 2025 · Mar 31, 2025 $7.82B
Total Liabilities Q1 2025 · Dec 31, 2024 $7.88B
Current Assets Q1 2025 · Mar 31, 2025 $1.84B
Current Assets Q1 2025 · Dec 31, 2024 $1.8B
Total Assets Q1 2025 · Mar 31, 2025 $17.61B
Total Assets Q1 2025 · Dec 31, 2024 $18.22B
Shares Diluted Q1 2025 · Mar 31, 2024 597.48M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 $664.64M
Stockholders Equity Q1 2025 · Mar 31, 2024 $9.86B
Stockholders Equity Q1 2025 · Dec 31, 2023 $10.08B
Eps Diluted Q1 2025 · Mar 31, 2024 $0.01
Eps Basic Q1 2025 · Mar 31, 2024 $0.01
Sga Expense Q1 2025 · Mar 31, 2024 $57.65M
Rd Expense Q1 2025 · Mar 31, 2024 $500K
Net Income Q1 2025 · Mar 31, 2024 $4.78M
Operating Income Q1 2025 · Mar 31, 2024 −$73.77M
Revenue Q1 2025 · Mar 31, 2024 $567.98M